Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Psychiatry 148, 8794
Neither tirzepatide nor semaglutide increased the risk for serious adverse events or severe hypoglycaemia
Ozempic triggers multiple physiological responses throughout the body, primarily affecting these systems: Insulin Secretion Enhancement : Stimulates pancreatic beta cells to release insulin in response to elevated blood glucose levels, providing glucose-dependent control that reduces hypoglycemia risk Glucagon Suppression : Reduces the release of glucagon from pancreatic alpha cells, preventing the liver from producing excess glucose during meals Gastric Emptying Delay : slows the rate at which food moves from the stomach to the small intestine, creating prolonged feelings of fullness Appetite Regulation : Acts on brain centers controlling hunger and satiety, reducing overall food intake and cravings Hepatic Glucose Production : Decreases the livers glucose output through both direct and indirect mechanisms The medication achieves its effects through once-weekly subcutaneous injections, with the FDA approving doses of 0.5 mg and 1.0 mg for diabetes management
2014 : Approved for weight management
